Skip to main navigation
Centessa Pharmaceuticals
  • About Us
  • Team
  • Programs and Pipeline
    • Summary and Pipeline
    • Orexin Receptor 2 Agonist Program
    • LockBody® Technology Platform
  • Patients
  • Investors
  • News
  • Careers
  • About Us
  • Team
  • Programs and Pipeline
    • Summary and Pipeline
    • Orexin Receptor 2 Agonist Program
    • LockBody® Technology Platform
  • Patients
  • Investors
  • News
  • Careers
Centessa Pharmaceuticals
  • About Us
  • Team
  • Programs and Pipeline
    • Summary and Pipeline
    • Orexin Receptor 2 Agonist Program
    • LockBody® Technology Platform
  • Patients
  • Investors
  • News
  • Careers
Centessa Pharmaceuticals
  • About Us
  • Team
  • Programs and Pipeline
    • Summary and Pipeline
    • Orexin Receptor 2 Agonist Program
    • LockBody® Technology Platform
  • Patients
  • Investors
  • News
  • Careers
  • About Us
  • Team
  • Programs and Pipeline
    • Summary and Pipeline
    • Orexin Receptor 2 Agonist Program
    • LockBody® Technology Platform
  • Patients
  • Investors
  • News
  • Careers
Centessa Pharmaceuticals
  • About Us
  • Team
  • Programs and Pipeline
    • Summary and Pipeline
    • Orexin Receptor 2 Agonist Program
    • LockBody® Technology Platform
  • Patients
  • Investors
  • News
  • Careers
  • Overview
  • Press Releases
  • Events & Presentations
  • Financials
    SEC Filings Annual Reports
  • Stock Info
    Stock Quote & Chart Historical Price Lookup Analyst Coverage
  • Governance
    Documents & Charters Management Team Board of Directors Committee Composition
  • Annual General Meeting
  • Shareholder Resources
    FAQs Email Alerts Contact Us RSS Feeds PFIC Information

Publications

bmj
February 18, 2021
Targeting human plasmacytoid dendritic cells through BDCA2 prevents skin inflammation and fibrosis in a novel xenotransplant mouse model of scleroderma
Ross, R., et al. BMJ Journals
pubmed
January 6, 2020
Comparison of the Hepatotoxic Potential of Two Treatments for Autosomal-Dominant Polycystic Kidney DiseaseUsing Quantitative Systems Toxicology Modeling
Woodhead, J.L., et al. PubMed
pubmed
December 26, 2019
Lixivaptan, a New Generation Diuretic, Counteracts Vasopressin-Induced Aquaporin-2 Trafficking and Function in Renal Collecting Duct Cells
Di Mise, A., et al. PubMed
pubmed
May 22, 2019
Effect of a Vasopressin V2 Receptor Antagonist on Polycystic Kidney Disease Development in a Rat Model
Wang, X., et al. PubMed
blood
January 5, 2017
Design and characterization of an APC-specific serpin for the treatment of hemophilia
Polderdijk, S., et al. Blood
Print Page
FAQs
Email Alerts
Contact Us
RSS Feeds

Centessa Pharmaceuticals
  • About Us
  • Team
  • Programs and Pipeline
  • Investors
  • News
  • Careers
Menu
  • About Us
  • Team
  • Programs and Pipeline
  • Investors
  • News
  • Careers
  • Privacy Notices
  • PFIC Information
Contact Us
Follow Us